Press release
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market is projected to reach USD 6.54 billion by 2034
Systemic Sclerosis-Associated Interstitial Lung Disease
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71355
SSc-ILD is the leading cause of morbidity and mortality in systemic sclerosis patients. It involves progressive fibrosis and inflammation of the lungs, reducing lung capacity, impairing gas exchange, and increasing the risk of respiratory failure. Early intervention and multidisciplinary care have dramatically improved survival, and the availability of disease-modifying therapeutics has transformed the treatment landscape.
Key Market Highlights
• 2024 Market Size: USD 3.12 billion
• 2034 Forecast: USD 6.54 billion
• CAGR (2025-2034): 7.8%
• Primary Therapy Classes: Antifibrotics & immunomodulators
• Fastest-Growing Segment: Biologics targeting immune and fibrotic pathways
Epidemiology & Patient Insights
1. Prevalence of Systemic Sclerosis
• Systemic sclerosis affects 50-300 per million people globally.
• Up to 80% develop some degree of ILD.
• Approximately 35-45% develop clinically significant SSc-ILD requiring long-term therapy.
2. High-Risk Groups
• Diffuse cutaneous systemic sclerosis
• Patients with anti-Scl-70 (topoisomerase I) antibodies
• Individuals with early, rapidly progressive disease
3. Disease Burden
SSc-ILD leads to:
• Chronic dyspnea
• Persistent cough
• Progressive decline in forced vital capacity (FVC)
• Increased hospitalization and mortality
Early diagnosis via HRCT and PFTs is key to slowing progression.
Market Growth Drivers
1. Increasing Adoption of Antifibrotic Therapies
Drugs that reduce lung fibrosis progression are now widely used in systemic sclerosis patients.
2. Advances in Immunomodulatory Treatments
Immunosuppressants such as MMF and cyclophosphamide remain foundational, while biologics and targeted therapies are growing rapidly.
3. Improved Screening & Diagnosis
Early use of:
• High-resolution CT (HRCT)
• Pulmonary function tests (PFTs)
• Autoantibody panels
has increased treatment initiation at earlier stages.
4. Rising Awareness of Connective Tissue Disease-ILD
Rheumatologists and pulmonologists increasingly collaborate for early disease management.
5. Strong Pipeline of Novel Therapies
Several antifibrotic, anti-inflammatory, and immune pathway modulators are in late-stage clinical trials.
Market Restraints
• High treatment costs for biologics and antifibrotics
• Slow disease recognition in early stages
• Limited specialist availability in developing regions
• Long-term safety concerns with chronic immunosuppressive therapy
Market Opportunities
1. Next-Generation Antifibrotic Drugs
Better tolerability and enhanced FVC preservation are key innovation areas.
2. Precision Immunology
Cytokine profiling and genomic markers will support personalized therapy decisions.
3. Combination Therapy Approaches
Emerging data support using antifibrotic + immunomodulator combinations.
4. AI-Enabled Early Detection
AI-enhanced CT scan interpretation can detect ILD earlier than conventional methods.
5. Telehealth & Remote Monitoring
SSc-ILD patients benefit from remote lung function monitoring and symptom tracking.
Segmentation Overview
By Treatment Type
• Antifibrotics
• Immunosuppressants
• Biologics
• Corticosteroids
• Oxygen therapy
• Supportive care & rehabilitation
By Disease Severity
• Mild
• Moderate
• Severe / progressive
By Route of Administration
• Oral
• Injectable
• Infusion-based biologics
By End User
• Hospitals
• Pulmonary care centers
• Rheumatology clinics
• Specialty pharmacies
Explore Full Report here: https://exactitudeconsultancy.com/reports/71355/systemic-sclerosis-associated-interstitial-lung-disease-market
Regional Insights
North America - Largest Market
Strong adoption of antifibrotics, advanced rheumatology-pulmonology networks, and high disease awareness.
Europe - Structured ILD Care Pathways
Standardized guidelines and robust clinical research in systemic sclerosis and ILD.
Asia Pacific - Fastest Growing Market
Rising autoimmune disease prevalence, improved ILD screening, and expanding healthcare access.
Latin America - Growing Focus on ILD Management
Improved specialist availability and better access to immunosuppressant therapy.
Middle East & Africa - Developing
Gradual improvements in autoimmune disease diagnostics and pulmonary care.
Competitive Landscape
Major companies active in the SSc-ILD treatment market include:
• Boehringer Ingelheim
• Roche
• Novartis
• Bristol Myers Squibb
• Merck
• GSK
• Pfizer
• Sanofi
• UCB Pharma
• Bayer
Focus areas: antifibrotics, cytokine-blocking biologics, immune modulators, and precision fibrosis therapies.
Recent Market Developments
• Expansion of antifibrotic therapies into SSc-ILD and mixed ILD populations
• Clinical progress in biologics targeting immune pathways involved in fibrosis
• Increased adoption of combination immunosuppression + antifibrotic regimens
• New diagnostic algorithms using HRCT + AI tools
• Enhanced integration of pulmonary rehabilitation into SSc-ILD care
Future Outlook (2025-2034)
The SSc-ILD Market will expand rapidly as:
• Antifibrotics gain broader acceptance
• Biologics reshape progressive ILD treatment
• AI-driven early detection becomes standard
• Combination therapy improves patient outcomes
• Global access to autoimmune disease care expands
By 2034, the market is projected to reach USD 6.54 billion, supported by innovation in fibrosis management and rising global disease awareness.
This report is also available in the following languages : Japanese (全身性硬化症関連間質性肺疾患市場), Korean (전신성 경화증 관련 간질성 폐질환 시장), Chinese (系统性硬化症相关间质性肺病市场), French (Marché des maladies pulmonaires interstitielles associées à la sclérose systémique), German (Markt für interstitielle Lungenerkrankungen im Zusammenhang mit systemischer Sklerose), and Italian (Mercato della malattia polmonare interstiziale associata alla sclerosi sistemica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71355
Our More Reports:
Connective Tissue Disease associated with Interstitial Lung Disease Market
https://exactitudeconsultancy.com/reports/71473/connective-tissue-disease-associated-with-interstitial-lung-disease-market
Progressive Fibrosing Interstitial Lung Disease Market
https://exactitudeconsultancy.com/reports/71479/progressive-fibrosing-interstitial-lung-disease-market
MAC Lung Disease Market
https://exactitudeconsultancy.com/reports/71506/mac-lung-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market is projected to reach USD 6.54 billion by 2034 here
News-ID: 4309708 • Views: …
More Releases from Exactitude Consultancy
Morquio Syndrome (MPS IV) Market CAGR of approximately 6%-7% during 2025-2032
Market Overview
The Morquio Syndrome (MPS IV) market is experiencing consistent growth driven by improved disease awareness, expanding access to enzyme replacement therapy (ERT), advancements in genetic diagnostics, and ongoing clinical research into next-generation therapies. Morquio Syndrome, a rare lysosomal storage disorder, leads to impaired degradation of keratan sulfate, resulting in skeletal abnormalities, growth delays, and multi-systemic complications.
The global Morquio Syndrome market is estimated to be around USD 550-600 million in…
Limb-Girdle Muscular Dystrophy (LGMD) Market to reach USD 1.96 billion by 2032, …
Market Overview
The Limb-Girdle Muscular Dystrophy (LGMD) market continues to advance as improved diagnostic technologies, rising rare-disease awareness, and rapid progress in gene-based therapies reshape treatment opportunities. LGMD consists of a diverse group of inherited neuromuscular disorders that cause progressive weakness of the hip and shoulder muscles. Growing investments in rare-disease R&D, supportive regulatory frameworks, and a strengthening therapeutic pipeline are key factors driving market expansion.
Industry estimates indicate that the LGMD…
Immune Thrombocytopenia (ITP) Market is projected to reach USD 4.89 billion by 2 …
The global Immune Thrombocytopenia (ITP) Market was valued at USD 2.46 billion in 2024 and is projected to reach USD 4.89 billion by 2034, growing at a CAGR of 7.1% during the forecast period (2025-2034). Market growth is fueled by advancements in targeted therapies, increasing diagnosis rates, growing awareness among physicians and patients, and expanding use of thrombopoietin receptor agonists (TPO-RAs) for chronic ITP.
Download Full PDF Sample Copy of Market…
Hereditary Angioedema (HAE) Market Forecast 2024-2034
Market Overview
The Hereditary Angioedema (HAE) Market is expanding rapidly due to increased diagnosis rates, patient awareness, and the availability of advanced on-demand and prophylactic therapies.
HAE is a rare, genetic disorder characterized by recurrent episodes of severe swelling affecting the skin, gastrointestinal tract, and upper airways, often caused by C1-inhibitor deficiency or dysfunction. Rising adoption of genetic testing, improved treatment guidelines, and the introduction of next-generation monoclonal antibodies and oral kallikrein…
More Releases for ILD
PH-ILD Market Set to Grow Substantially Through 2034, DelveInsight Projects
DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pulmonary Hypertension Associated with Interstitial Lung Disease, historical and forecasted epidemiology as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the PH-ILD market outlook, drug uptake,…
Connective tissue disease-associated ILD (CTD-ILD) Patient Pool Analysis Market …
Connective tissue disease-associated interstitial lung disease (CTD-ILD) refers to a group of serious lung complications arising from autoimmune conditions such as rheumatoid arthritis, systemic sclerosis, lupus, and dermatomyositis. Characterized by progressive scarring and impaired lung function, CTD-ILD is one of the most severe extra-pulmonary manifestations of connective tissue disorders.
Download Full PDF Sample Copy of Market Report @https://exactitudeconsultancy.com/request-sample/71523
As diagnostic techniques improve and awareness among clinicians increases, more CTD-ILD cases are being…
Systemic Sclerosis-Associated ILD Market to Grow to USD 8.1 Billion by 2034
Systemic sclerosis (SSc) is a rare, chronic autoimmune disease that causes fibrosis of the skin and internal organs. Among its most serious complications is interstitial lung disease (ILD), which remains a leading cause of mortality in patients. The condition is complex and progressive, creating significant unmet medical needs and healthcare burdens.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71355
In recent years, the SSc-ILD market has gained global attention, with…
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market Massive …
Introduction
Systemic sclerosis (scleroderma) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage, and immune system dysfunction. Among its most serious complications is systemic sclerosis-associated interstitial lung disease (SSc-ILD), a progressive and potentially fatal condition that significantly reduces quality of life and survival rates.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71331
Historically, treatment relied on immunosuppressants such as cyclophosphamide and mycophenolate mofetil, but…
Global CMP Slurry for ILD and STI Market Research Report 2024-2030
Global Leading Market Research Publisher QYResearch announces the release of its lastest report "Global CMP Slurry for ILD and STI Market Report, History and Forecast 2019-2030, Breakdown Data by Manufacturers, Key Regions, Types and Application". Based on historical analysis (2019-2023) and forecast calculations (2024-2030), this report provides a comprehensive analysis of the global CMP Slurry for ILD and STI market, including market size, share, demand, industry development status, and forecasts…
Global Interstitial Lung Disease (ILD) Industry Market Research Report from 2020 …
Global Interstitial Lung Disease (ILD)Market Overview:
The latest report on the global Interstitial Lung Disease (ILD)marketsuggests a positive growth rate in the coming years. Analysts have studied the historical data and compared it with the current market scenario to determine the trajectory this market will take in the coming years. The investigative approach taken to understand the various aspects of the market is aimed at giving the readers a holistic view…
